Boehringer Ingelheim sales and marketing update

Boehringer launched Ofev nintedanib in the U.S. to treat idiopathic pulmonary fibrosis (IPF). Ofev has Orphan Drug and breakthrough therapy status in the U.S. for the indication. Nintedanib is also u...